Association of PPARG Pro12Ala polymorphism with insulin sensitivity and body mass index in patients with polycystic ovary syndrome

Baldani,Dinka Pavicic; Skrgatic,Lana; Cerne,Jasmina Z.; Ferk,Polonca; Simunic,Velimir; Gersak,Ksenija

doi:10.3892/br.2013.215

Association of PPARG Pro12Ala polymorphism with insulin sensitivity and body mass index in patients with polycystic ovary syndrome

Authors:
- Dinka Pavicic Baldani
- Lana Skrgatic
- Jasmina Z. Cerne
- Polonca Ferk
- Velimir Simunic
- Ksenija Gersak
View Affiliations

Affiliations: Department of Obstetrics and Gynaecology, Division of Human Reproduction, University of Zagreb Medical School, University of Zagreb Medical Centre, Zagreb, Croatia, Department of Obstetrics and Gynaecology, Division of Medical Genetics, University of Ljubljana Medical Centre, Ljubljana, Slovenia, Department of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Maribor, Maribor, Slovenia
Published online on: December 30, 2013 https://doi.org/10.3892/br.2013.215
Pages: 199-206

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Insulin resistance is one of the key factors in the pathogenesis of polycystic ovary syndrome (PCOS). The peroxisome proliferator‑activated receptor gamma (PPARG) plays a role in the regulation of insulin sensitivity. The aim of the present study was to establish a possible association of the PPARG Pro12Ala polymorphism with PCOS and its effect on family and personal history, as well as on the metabolic and endocrine parameters in PCOS patients. A total of 151 PCOS patients and 179 healthy women of reproductive age were enrolled. History, body mass index (BMI), waist‑to‑hip ratio and the presence of phenotypic hyperandrogenism were recorded. Hormonal, metabolic and biochemical profiles were assessed. A molecular analysis for the genetic polymorphism was performed. One third (29.8%) of the PCOS patients were found to be carriers of at least one variant of the Ala allele (X/Ala), while 70.2% carried two wild‑type Pro alleles (Pro/Pro), with an equal distribution observed in the control group. The PCOS patients carrying the X/Ala alleles exhibited lower serum fasting insulin levels, homeostatic model assessment of insulin resistance (HOMA‑IR) and BMI compared to Pro/Pro carriers. This finding was significant only in the lean PCOS group. The polymorphic genotype exerted no effect on history, hormonal and clinical hyperandrogenism, lipid status or C‑reactive protein, leptin, adiponectin, resistin and ghrelin serum levels in women with PCOS. In conclusion, although the PPARG Pro12Ala polymorphism is not a major determinant of PCOS in the Croatian population, it may exert a positive effect on insulin sensitivity and BMI. As these associations were recorded exclusively in the lean group of patients with PCOS, this polymorphism potentially contributes to a protective role against hyperinsulinemia and obesity.

View Figures

View References

1	Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 19:41–47. 2004. View Article : Google Scholar
2	Diamanti-Kandarakis E and Piperi C: Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update. 11:631–643. 2005. View Article : Google Scholar : PubMed/NCBI
3	Alberti KG, Zimmet P and Shaw J: International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet Med. 24:451–463. 2007. View Article : Google Scholar : PubMed/NCBI
4	Carmina E, Orio F, Palomba S, et al: Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 152:389–394. 2005. View Article : Google Scholar : PubMed/NCBI
5	Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK and Imperial J: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 22:141–146. 1999. View Article : Google Scholar : PubMed/NCBI
6	Schmidt J, Landin-Wilhelmsen K, Brannstrom M and Dahlgren E: Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab. 96:3794–3803. 2011.PubMed/NCBI
7	Kadowaki T, Hara K, Kubota N, et al: The role of PPARgamma in high-fat diet-induced obesity and insulin resistance. J Diabetes Complications. 16:41–45. 2002. View Article : Google Scholar : PubMed/NCBI
8	Zhang J, Fu M, Cui T, et al: Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA. 101:10703–10708. 2004. View Article : Google Scholar : PubMed/NCBI
9	Elbrecht A, Chen Y, Cullinan CA, et al: Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun. 224:431–437. 1996. View Article : Google Scholar : PubMed/NCBI
10	Rangwala SM and Lazar MA: Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci. 25:331–336. 2004. View Article : Google Scholar : PubMed/NCBI
11	Deeb SS, Fajas L, Nemoto M, et al: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 20:284–287. 1998. View Article : Google Scholar : PubMed/NCBI
12	Altshuler D, Hirschhorn JN, Klannemark M, et al: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 26:76–80. 2000. View Article : Google Scholar : PubMed/NCBI
13	Hara K, Okada T, Tobe K, et al: The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun. 271:212–216. 2000. View Article : Google Scholar : PubMed/NCBI
14	Jacob S, Stumvoll M, Becker R, et al: The PPARgamma2 polymorphism pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res. 32:413–416. 2000. View Article : Google Scholar : PubMed/NCBI
15	Doney AS, Fischer B, Leese G, Morris AD and Palmer CN: Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol. 24:2403–2407. 2004. View Article : Google Scholar : PubMed/NCBI
16	Demers A, Caron V, Rodrigue-Way A, Wahli W, Ong H and Tremblay A: A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages. PLoS One. 4:e77282009. View Article : Google Scholar : PubMed/NCBI
17	Haseeb A, Iliyas M, Chakrabarti S, et al: Single-nucleotide polymorphisms in peroxisome proliferator-activated receptor gamma and their association with plasma levels of resistin and the metabolic syndrome in a South Indian population. J Biosci. 34:405–414. 2009. View Article : Google Scholar
18	Simon I, Vendrell J, Gutierrez C, et al: Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma is associated with increased leptin levels in women with type-2 diabetes mellitus. Horm Res. 58:143–149. 2002. View Article : Google Scholar : PubMed/NCBI
19	Yamamoto Y, Hirose H, Miyashita K, et al: PPAR(gamma)2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism. 51:1407–1409. 2002. View Article : Google Scholar : PubMed/NCBI
20	Baldani DP, Skrgatic L, Goldstajn MS, et al: Clinical and biochemical characteristics of polycystic ovary syndrome in Croatian population. Coll Antropol. 36:1413–1418. 2012.PubMed/NCBI
21	Ferriman D and Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 21:1440–1447. 1961. View Article : Google Scholar : PubMed/NCBI
22	Vermeulen A, Verdonck L and Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 84:3666–3672. 1999. View Article : Google Scholar : PubMed/NCBI
23	Friedewald WT, Levy RI and Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:499–502. 1972.PubMed/NCBI
24	Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ and Ehrmann DA: Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab. 87:772–775. 2002.PubMed/NCBI
25	Korhonen S, Heinonen S, Hiltunen M, et al: Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Hum Reprod. 18:540–543. 2003. View Article : Google Scholar : PubMed/NCBI
26	Yilmaz M, Ergun MA, Karakoc A, Yurtcu E, Cakir N and Arslan M: Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol. 22:336–342. 2006. View Article : Google Scholar : PubMed/NCBI
27	Christopoulos P, Mastorakos G, Gazouli M, et al: Peroxisome proliferator-activated receptor-gamma and -delta polymorphisms in women with polycystic ovary syndrome. Ann NY Acad Sci. 1205:185–191. 2010. View Article : Google Scholar : PubMed/NCBI
28	Hahn S, Fingerhut A, Khomtsiv U, et al: The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 62:573–579. 2005. View Article : Google Scholar
29	Koika V, Marioli DJ, Saltamavros AD, et al: Association of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 with decreased basic metabolic rate in women with polycystic ovary syndrome. Eur J Endocrinol. 161:317–322. 2009. View Article : Google Scholar
30	Orio F Jr, Matarese G, Di Biase S, et al: Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab. 88:5887–5892. 2003. View Article : Google Scholar : PubMed/NCBI
31	Orio F Jr, Palomba S, Cascella T, et al: Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab. 89:5110–5115. 2004. View Article : Google Scholar : PubMed/NCBI
32	San-Millan JL and Escobar-Morreale HF: The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): an original case-control study followed by systematic review and meta-analysis of existing evidence. Clin Endocrinol (Oxf). 72:383–392. 2010. View Article : Google Scholar
33	Tok EC, Aktas A, Ertunc D, Erdal EM and Dilek S: Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-gamma2 Pro12Ala genotype. Hum Reprod. 20:1590–1595. 2005. View Article : Google Scholar : PubMed/NCBI
34	Xita N, Lazaros L, Georgiou I and Tsatsoulis A: The Pro12Ala polymorphism of the PPAR-gamma gene is not associated with the polycystic ovary syndrome. Hormones (Athens). 8:267–272. 2009.PubMed/NCBI
35	He J, Wang L, Liu J, Liu F and Li X: A meta-analysis on the association between PPAR-gamma Pro12Ala polymorphism and polycystic ovary syndrome. J Assist Reprod Genet. 29:669–677. 2012. View Article : Google Scholar : PubMed/NCBI
36	Zhang H, Bi Y, Hu C, Lu W and Zhu D: Association between the Pro12Ala polymorphism of PPAR-gamma gene and the polycystic ovary syndrome: a meta-analysis of case-control studies. Gene. 503:12–17. 2012. View Article : Google Scholar : PubMed/NCBI
37	Bidzinska-Speichert B, Demissie M, Tworowska U, et al: Leptin level and the PPARgamma2 Pro12Ala and Pro115Gln polymorphisms in women with functional hyperandrogenism. Preliminary report. Przegl Lek. 62:833–837. 2005.(In Polish).
38	Dragojevic J, Ostanek B, Mencej-Bedrac S, Komadina R, Prezelj J and Marc J: PPARG gene promoter polymorphism is associated with non-traumatic hip fracture risk in the elderly Slovenian population: a pilot study. Clin Biochem. 44:1085–1089. 2011. View Article : Google Scholar : PubMed/NCBI
39	Antoine HJ, Pall M, Trader BC, Chen YD, Azziz R and Goodarzi MO: Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertil Steril. 87:862–869. 2007. View Article : Google Scholar
40	Lehrke M and Lazar MA: The many faces of PPARgamma. Cell. 123:993–999. 2005. View Article : Google Scholar : PubMed/NCBI
41	Ek J, Urhammer SA, Sorensen TI, Andersen T, Auwerx J and Pedersen O: Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia. 42:892–895. 1999. View Article : Google Scholar : PubMed/NCBI
42	Kao WH, Coresh J, Shuldiner AR, et al; Atherosclerosis Risk in Communities Study. Pro12Ala of the peroxisome proliferator-activated receptor-gamma2 gene is associated with lower serum insulin levels in nonobese African Americans: the Atherosclerosis Risk in Communities Study. Diabetes. 52:1568–1572. 2003. View Article : Google Scholar
43	Masud S and Ye S; SAS Group. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet. 40:773–780. 2003. View Article : Google Scholar : PubMed/NCBI
44	Jaziri R, Lobbens S, Aubert R, et al; DESIR Study Group. The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Diabetes. 55:1157–1162. 2006.
45	Huguenin GV and Rosa G: The Ala allele in the PPAR-gamma2 gene is associated with reduced risk of type 2 diabetes mellitus in Caucasians and improved insulin sensitivity in overweight subjects. Br J Nutr. 104:488–497. 2010. View Article : Google Scholar : PubMed/NCBI
46	Luan J, Browne PO, Harding AH, et al: Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes. 50:686–689. 2001. View Article : Google Scholar : PubMed/NCBI
47	Garaulet M, Smith CE, Hernandez-Gonzalez T, Lee YC and Ordovas JM: PPARgamma Pro12Ala interacts with fat intake for obesity and weight loss in a behavioural treatment based on the Mediterranean diet. Mol Nutr Food Res. 55:1771–1779. 2011. View Article : Google Scholar : PubMed/NCBI
48	Ranilovic J, Markovina J, Znidar K and Colic Baric I: Attitudes to healthy eating among a representative sampling of Croatian adults: a comparison with Mediterranean countries. Int J Food Sci Nutr. 60:11–29. 2009. View Article : Google Scholar : PubMed/NCBI
49	Boulman N, Levy Y, Leiba R, et al: Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 89:2160–2165. 2004. View Article : Google Scholar : PubMed/NCBI
50	Bidzinska-Speichert B, Lenarcik A, Tworowska-Bardzinska U, et al: Pro12Ala PPAR gamma2 gene polymorphism in women with polycystic ovary syndrome. Ginekol Pol. 82:426–429. 2011.PubMed/NCBI
51	Kondo H, Shimomura I, Matsukawa Y, et al: Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes. 51:2325–2328. 2002. View Article : Google Scholar : PubMed/NCBI
52	Kubota N, Terauchi Y, Yamauchi T, et al: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 277:25863–25866. 2002. View Article : Google Scholar : PubMed/NCBI
53	Weyer C, Funahashi T, Tanaka S, et al: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 86:1930–1935. 2001. View Article : Google Scholar : PubMed/NCBI
54	Wang C, Zhai F, Chi Y and Wang G: Association of Pro12Ala mutation in peroxisome proliferator-activated receptor gamma 2 with obesity and diabetes in Chinese population. J Hyg Res. 33:317–320. 2004.(In Chinese).
55	Botchkarev VA and Paus R: Molecular biology of hair morphogenesis: development and cycling. J Exp Zool B Mol Dev Evol. 298:164–180. 2003. View Article : Google Scholar : PubMed/NCBI
56	Smith KJ, Dipreta E and Skelton H: Peroxisomes in dermatology. Part II. J Cutan Med Surg. 5:315–322. 2001. View Article : Google Scholar
57	Sas T, Mulder P, Aanstoot HJ, et al: Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clin Endocrinol (Oxf). 54:243–251. 2001. View Article : Google Scholar : PubMed/NCBI
58	Leunissen RW, Oosterbeek P, Hol LK, Hellingman AA, Stijnen T and Hokken-Koelega AC: Fat mass accumulation during childhood determines insulin sensitivity in early adulthood. J Clin Endocrinol Metab. 93:445–451. 2008. View Article : Google Scholar : PubMed/NCBI
59	Eriksson JG, Lindi V, Uusitupa M, et al: The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on insulin sensitivity and insulin metabolism interact with size at birth. Diabetes. 51:2321–2324. 2002. View Article : Google Scholar : PubMed/NCBI
60	Ibanez L, Potau N, Francois I and de Zegher F: Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab. 83:3558–3562. 1998. View Article : Google Scholar : PubMed/NCBI